miR-20b downregulates polymerases κ and θ in XP-V tumor cells
- Authors:
- Published online on: April 18, 2016 https://doi.org/10.3892/ol.2016.4447
- Pages: 3790-3794
Abstract
Introduction
Xeroderma pigmentosum (XP) is a sun-toxicity disease. A total of 8 subtypes (from XP-A to XP-G and XP-V) of this disease have been identified by their different pathogenic genes (1,2). The pathogenic mechanisms of almost all these subtypes result from a defect in nucleotide excision repair (3), except XP-V subtype, which results from a translesion synthesis (TLS) defect (4). XP-V is a common subtype (21%) in XP disease, and has a similar phenotype to other subtypes (2), including sun sensitivity, photophobia, early onset of freckling, and subsequent neoplastic changes in sun-exposed skin (5,6). The majority of studies have demonstrated that XP-V disease is a result of mutations in the POLH gene (encoding DNA polymerase η). Polymerase η is the main DNA polymerase responsible for TLS, and its defect could apparently reduce TLS efficiency and increase mismatch in DNA replication. These phenomena result in genomic instability, leading to a high incidence of tumors in patients (7–15). It has been previously demonstrated that polymerase η has defective expression in XP-V cells and that certain other polymerases involving TLS are unusually expressed, such as polymerase κ and ζ (encoded by POLK and REV3 l, respectively) (16). An additional polymerase, polymerase θ (encoded by POLQ), also has low expression in XP-V cells and tumor tissue and has the same function as polymerase η, which is to generate A/T mutations during the somatic hypermutation of immunoglobulin (Ig) genes (16,17). Given that a number of polymerases change their expression in XP-V cells and tumor tissue, certain factors may co-regulate the expression of these polymerases.
MicroRNAs (miRNAs) are endogenous, small non-coding RNAs that regulate translation and degradation of mRNAs at the post-transcriptional level (18). Protein expression from hundreds of genes are directly suppressed, albeit relatively mildly, by a single miRNA (19). Dysregulated miRNAs are correlated with various cancers and may function as tumor suppressors or oncogenes, depending on the function of their targets and cellular context (20). Therefore, certain miRNAs with unusual expression may explain the changes in expression of these polymerases in XP-V tumor that accelerate DNA mismatch.
Previous studies have mainly verified POLH mutation as an etiological factor of developing XP-V tumors (7–9,14). In the present study, polymerase-suppressive miRNAs associated with XP-V tumor were identified by analyzing miRNAs that may directly regulate DNA polymerases with unusual expression in XP-V tumor cells. miR-20b-5p was identified to be a polymerase suppressor by directly targeting POLK and POLQ.
Materials and methods
Prediction of miRNA as co-suppressor of POLK, REV3 l, and POLQ
POLK, REV3 l and POLQ all demonstrate low expression in XP-V tumor cells (16). Accordingly, Targetscan (http://www.targetscan.org), miRDB (http://mirdb.org/miRDB), and miRanda (http://www.microrna.org) were used to predict miRNA co-targeting these three genes.
Cell culture
All cells including XP-V tumor fibroblast cell lines, human skin fibroblasts (HSFs), and HeLa cells were cultured in DMEM supplemented with 20% FBS (HyClone, Logan, UT, USA). HeLa cells and HSFs were purchased from the cell bank of the Chinese Academy Of Sciences (Beijing, China). XP-V tumor fibroblast cell lines (XP30RO, XP1CH, and XP1SF) were purchased from The Coriell Institute (Camden, NJ, USA). Cells were incubated at 37°C in 5% CO2.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for candidate miRNAs in XP-V cells
QIAgen miScript miRNA PCR Arrays kit (QIAgen Inc., Hilden, Germany) was used to extract, reverse transcribe and amplify total miRNAs in XP-V cell lines and HSFs according to the manufacturer's protocol. U6 was used as an endogenous control to normalize the amount of total miRNA in each sample. ABI 7500 Real-time PCR System (Applied Biosystems, Carlsbad, CA, USA) was used to analyze the data. Primers were synthesized by GenePharma (Shanghai, China) and the sequences are presented in Table I. To identify differences in miRNA expression, samples of HSF cells were defined as reference samples, and the quantity of all tested miRNAs in the reference sample was defined as ‘1.0.’ Student's t-test was used to compare relative expression levels between XP-V cell lines and HSF control cells.
Transfection
HeLa cells were transfected with 200 nM candidate miRNA, miR-NC mimics, or miRNA inhibitor (GenePharma, Shanghai, China) using Turbofect transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA) when cells reached 70–80% confluence.
Western blot analysis
All cells were harvested using RIPA lysis buffer (Beyotime, Shanghai, China). Then, 1% PMSF (Bioprimacy Co., Ltd., Wuhan, China) was added directly prior to use. Protein concentration was measured using BCA protein assay (Thermo Fisher Scientific, Inc.). Protein was loaded onto 10% SDS-PAGE gel (Beyotime, Shanghai, China) and then transferred to PVDF membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The blot was blocked with 5% skim milk for 2 h and then probed with primary mouse monoclonal polymerase κ (dilution, 1:6,000; catalog no., ab57070), rabbit polyclonal polymerase θ (dilution, 1:3,000; catalog no., ab80906), and mouse monoclonal β-actin (dilution, 1:8,000; catalog no., ab8226) antibodies (Abcam, Cambridge, UK). After incubation at 4°C overnight, the blot was washed with TBST and incubated in secondary goat anti-mouse IgG-horseradish peroxidase antibody (dilution, 1:10,000; catalog no., sc-2005; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and goat anti-rabbit IgG-horseradish peroxidase antibody (dilution, 1:10,000; catalog no., sc-2004; Santa Cruz Biotechnology, Inc.) for 1 h at 25°C. The signal was developed with ECL reagent (Advansta, Inc., Menlo Park, CA, USA).
Luciferase reporter assay
The 3′-untranslated regions (UTRs) of POLK and POLQ were amplified using PCR from human genomic DNA and then ligated into pMIR-report (Ambion, Thermo Fisher Scientific, Inc.). Then, QuikChange Lightning site-directed mutagenesis kit (Stratagene Agilent Technologies, Santa Clara, CA, USA) was used to induce miR-20b-5p target sequences (complementary to the seed region for miR-20b-5p) to mutate TACTTT to GTGAAA in POLK and CACTTT to GTGAAA in POLQ. All constructs were confirmed by sequencing. Primers used are summarized in Table I. HeLa cells were co-transfected with wild-type or mutant 3′UTR luciferase reporter construct, the Renilla luciferase construct pRL-TK, and either miR-20b-5p or miR-NC mimics. Then, 48 h after transfection, luciferase activities were measured using the Dual Luciferase Reporter Assay System (Promega Corporation, Madison, WI, USA) and normalized by dividing the firefly luciferase activity with Renilla luciferase activity.
Statistical analyses
Values are expressed as mean ± standard deviation (SD) from triplicate experiments. Student's t-test was used to compare relative expression levels. Statistical analyses were performed by SPSS software, version 16.0 (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Using three web software predictions, it was found that no miRNA was predicted to target all three genes. Certain miRNAs were predicted to co-target POLQ and POLK but not REV3 L (Fig. 1). To find miRNAs co-regulating polymerases in XP-V tumor cells, only miRNAs that matched both POLK and POLQ from more than two software prediction results were selected. All other miRNAs were predicted to match only one of three genes, which were removed from the subsequent analysis. miR-520b, miR-520e, miR-302a, miR-302b, miR-302c, miR-302d, miR-93, miR-373, miR-548k, miR-20a, miR-20b, miR-106a, and miR-106b were chosen as candidate miRNAs.
The RT-qPCR results demonstrated that only miR-20a, miR-20b, miR-106a, miR-106b, and miR-548k were expressed at significantly different levels between XP-V cell lines and HSFs (Fig. 2).
The western blot analysis results verified that polymerase κ and θ were expressed at lower levels in XP-V tumor cell lines compared to the normal control cell line. Furthermore, when the above five miRNAs were transfected into HeLa cells, only miR-20b transfection resulted in reduced polymerase κ and θ levels (Fig. 3).
To determine whether such an inhibitory effect on translation was mediated by specific and direct interaction of miR-20b-5p with POLK and POLQ target site, luciferase reporter plasmids containing 3′UTR of both genes were constructed. The dual-luciferase assay demonstrated that the introduction of miR-20b-5p significantly reduced luciferase activity with respect to miR-NC, whereas such inhibitory effect was absent in cells transfected with reporter plasmids containing the mutant 3′UTR of both genes (Fig. 4).
Discussion
Low expression levels of polymerases in XP-V cells such as polymerase η, κ, and ζ may lead to a significant reduction in the accuracy of TLS in XP-V cells (21). Polymerase θ has also been indicated to serve a role in base excision repair, and lower expression of polymerase θ may also seem unfavorable for DNA replication repair (22). In XP-V tumor cells, polymerases ζ, κ, and θ are indeed expressed at low levels, in addition to the dysfunction of polymerase η that disrupts DNA lesion replication and promotes genetic instability (16,21). In the present study, no miRNA was predicted to co-regulate POLK and REV3 L expression, although these two genes both belonged to the Y-family of DNA polymerases (23). However, miR-20-5p was verified to function as co-suppressor of POLK and POLQ depending on its targets. The high expression of miR-20-5p in XP-V tumor cells could obviously decrease the expression of POLK and POLQ. Moreover, in XP-V tumor cells, these two polymerases with low expression may explain abnormal DNA replication repair apart from polymerase η dysfunction (21). Therefore, miR-20-5p may also serve an important role in XP-V tumors, accelerating DNA instability by down-regulating POLK and POLQ.
In summary, the current study demonstrated miR-20b-5p may co-regulate POLK and POLQ. Furthermore, miRNA may also be a novel factor that affect error-prone DNA replication in XP-V tumor cells.
Acknowledgements
The study was supported by grants from the National Natural Science Foundation of China (grant nos. 81400492 and 31400839).
References
Kraemer KH, Lee MM and Scotto J: Xeroderma pigmentosum. Cutaneous, ocular and neurologic abnormalities in 830 published cases. Arch Dermatol. 123:241–250. 1987. View Article : Google Scholar : PubMed/NCBI | |
Kraemer KH and DiGiovanna JJ; Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH and Stephens K: Xeroderma Pigmentosum. University of Washington. 1993–2015. 2003. | |
Berneburg M and Lehmann AR: Xeroderma pigmentosum and related disorders: Defects in DNA repair and transcription. Adv Genet. 43:71–102. 2001. View Article : Google Scholar : PubMed/NCBI | |
Cleaver JE: Xeroderma pigmentosum: Variants with normal DNA repair and normal sensitivity to ultraviolet light. J Invest Dermatol. 58:124–128. 1972. View Article : Google Scholar : PubMed/NCBI | |
Maher VM, Ouellette LM, Curren RD and McCormick JJ: Frequency of ultraviolet light-induced mutations is higher in xeroderma pigmentosum variant cells than in normal human cells. Nature. 261:593–595. 1976. View Article : Google Scholar : PubMed/NCBI | |
Myhr BC, Turnbull D and DiPaolo JA: Ultraviolet mutagenesis of normal and xeroderma pigmentosum variant human fibroblasts. Mutat Res. 62:341–353. 1979. View Article : Google Scholar : PubMed/NCBI | |
Masutani C, Kusumoto R, Yamada A, Dohmae N, Yokoi M, Yuasa M, Araki M, Iwai S, Takio K and Hanaoka F: The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature. 399:700–704. 1999. View Article : Google Scholar : PubMed/NCBI | |
Johnson RE, Kondratick CM, Prakash S and Prakash L: hRAD30 mutations in the variant form of xeroderma pigmentosum. Science. 285:263–265. 1999. View Article : Google Scholar : PubMed/NCBI | |
Inui H, Oh KS, Nadem C, Ueda T, Khan SG, Metin A, Gozukara E, Emmert S, Slor H, Busch DB, et al: Xeroderma pigmentosum-variant patients from America, Europe and Asia. J Invest Dermatol. 128:2055–2068. 2008. View Article : Google Scholar : PubMed/NCBI | |
Gratchev A, Strein P, Utikal J and Sergij G: Molecular genetics of Xeroderma pigmentosum variant. Exp Dermatol. 12:529–536. 2003. View Article : Google Scholar : PubMed/NCBI | |
Broughton BC, Cordonnier A, Kleijer WJ, Jaspers NG, Fawcett H, Raams A, Garritsen VH, Stary A, Avril MF, Boudsocq F, et al: Molecular analysis of mutations in DNA polymerase eta in xeroderma pigmentosum-variant patients. Proc Natl Acad Sci USA. 99:815–820. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kannouche P, Broughton BC, Volker M, Hanaoka F, Mullenders LH and Lehmann AR: Domain structure, localization and function of DNA polymerase eta, defective in xeroderma pigmentosum variant cells. Genes Dev. 15:158–172. 2001. View Article : Google Scholar : PubMed/NCBI | |
Yuasa M, Masutani C, Eki T and Hanaoka F: Genomic structure, chromosomal localization and identification of mutations in the xeroderma pigmentosum variant (XPV) gene. Oncogene. 19:4721–4728. 2000. View Article : Google Scholar : PubMed/NCBI | |
Tanioka M, Masaki T, Ono R, Nagano T, Otoshi-Honda E, Matsumura Y, Takigawa M, Inui H, Miyachi Y, Moriwaki S and Nishigori C: Molecular analysis of DNA polymerase eta gene in Japanese patients diagnosed as xeroderma pigmentosum variant type. J Invest Dermatol. 127:1745–1751. 2007. View Article : Google Scholar : PubMed/NCBI | |
Johnson RE, Prakash S and Prakash L: Efficient bypass of a thymine-thymine dimer by yeast DNA polymerase, Poleta. Science. 283:1001–1004. 1999. View Article : Google Scholar : PubMed/NCBI | |
Guo J, Zhou G, Zhang W, Song Y and Bian Z: A novel mutation causes XP-V disease and XP-V tumor proneness may involve imbalance of numerous DNA polymerases. Oncol Lett. 6:1583–1590. 2013.PubMed/NCBI | |
Masuda K, Ouchida R, Hikida M, Kurosaki T, Yokoi M, Masutani C, Seki M, Wood RD, Hanaoka F and O-Wang J: DNA polymerases eta and theta function in the same genetic pathway to generate mutations at A/T during somatic hypermutation of Ig genes. J Biol Chem. 282:17387–17394. 2007. View Article : Google Scholar : PubMed/NCBI | |
Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI | |
Baek D, Villén J, Shin C, Camargo FD, Gygi SP and Bartel DP: The impact of microRNAs on protein output. Nature. 455:64–71. 2008. View Article : Google Scholar : PubMed/NCBI | |
Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI | |
Ziv O, Geacintov N, Nakajima S, Yasui A and Livneh Z: DNA polymerase zeta cooperates with polymerases kappa and iota in translesion DNA synthesis across pyrimidine photodimers in cells from XPV patients. Proc Natl Acad Sci USA. 106:11552–11557. 2009. View Article : Google Scholar : PubMed/NCBI | |
Yoshimura M, Kohzaki M, Nakamura J, Asagoshi K, Sonoda E, Hou E, Prasad R, Wilson SH, Tano K, Yasui A, et al: Vertebrate POLQ and POLbeta cooperate in base excision repair of oxidative DNA damage. Mol Cell. 24:115–125. 2006. View Article : Google Scholar : PubMed/NCBI | |
Ohmori H, Friedberg EC, Fuchs RP, Goodman MF, Hanaoka F, Hinkle D, Kunkel TA, Lawrence CW, Livneh Z, Nohmi T, et al: The Y-family of DNA polymerases. Mol Cell. 8:7–8. 2001. View Article : Google Scholar : PubMed/NCBI |